Entering text into the input field will update the search result below

Myriad and AstraZeneca expand companion diagnostic partnership

Apr. 01, 2015 8:50 AM ETMyriad Genetics, Inc. (MYGN) StockAZN, MYGNBy: Douglas W. House, SA News Editor3 Comments
  • Myriad Genetics (NASDAQ:MYGN) and AstraZeneca (NYSE:AZN) expand their companion diagnostic collaboration using Myriad's BRACAnalysis CDx test to prospectively identify patients with metastatic pancreatic cancer who may respond to treatment with AZN's Lynparza (olaparib).
  • BRACAnalysis CDx is an in vitro diagnostic device that detects and classifies variants of BRCA1 and BRCA2 genes using genomic DNA from whole blood specimens. The FDA approved it in December 2014 as a companion diagnostic for Lynparza for ovarian cancer.

Recommended For You

About MYGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MYGN--
Myriad Genetics, Inc.